Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2018 | 74 | 04 |

Tytuł artykułu

Non-specific inflammatory bowel diseases and the risk of tumour growth

Warianty tytułu

Języki publikacji



Inflammatory bowel disease (IBD), which includes mainly ulcerative colitis (UC) and Crohn’s disease (Lesniowski-Crohn’s, ChL-C, CD), is a chronic and recurrent inflammatory condition of the gastrointestinal tract with multifactorial causes. Both types of IBD are characterized by chronic inflammation with periods of remission and exacerbation. An increasing number of studies have recently shown that chronic inflammation plays an important role in the carcinogenesis of colorectal cancer (CRC), generating suitable microenvironments for the formation and progression of the disease. The main factors are chronic inflammation as well as the scope and duration of the disease. The pro-inflammatory interleukins IL-13, IL-8 and TNF-α play an important role in tumorigenesis. It is further emphasized that reactive oxygen species (ROS) and reactive nitrogen species produced by inflammatory cells may interact with key genes involved in carcinogenic pathways, such as TP53. Carcinogenesis in IBD involves proteins determined by the genes DLG5, OCTN and NOD2. Immunosuppressive drugs, such as thiopurines and methotrexate, may play a role in extra-intestinal tumour development by impairing the immune system and surveillance of tumour cells or by inducing DNA damage. Recognition of neoplastic changes associated with IBD is difficult due to the heterogeneity of the endoscopic image and variation in the diagnosis depending on the observer. Therefore surveillance of IBD patients by a multidisciplinary team is essential for early detection of the neoplastic process.








Opis fizyczny



  • Department of Public Health, Faculty of Health Sciences, Medical University of Lublin, W.Chodzki 1, 20-093 Lublin, Poland
  • Department of Biological Basis of Animal Production, Faculty of Biology, Animal Sciences and Bioeconomy, University of Life Sciences in Lublin, Akademicka 13, 20-950 Lublin, Poland
  • Department of Biochemistry and Toxicology, Faculty of Biology, Animal Sciences and Bioeconomy, University of Life Sciences in Lublin, Akademicka 13, 20-950 Lublin, Poland
  • Department of Biochemistry and Toxicology, Faculty of Biology, Animal Sciences and Bioeconomy, University of Life Sciences in Lublin, Akademicka 13, 20-950 Lublin, Poland
  • Department of Pathological Anatomy, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Gleboka 30, 20-033 Lublin, Poland


  • Abraham B. P.: Cancer surveillance in ulcerative colitis and Crohn’s disease: new strategies. Curr. Opin. Gastroenterol. 2016, 32, 32-37.
  • Althumairi A. A., Lazarev M. G., Gearhart S. L.: Inflammatory bowel disease associated neoplasia: A surgeon’s perspective. World J. Gastroenterol. 2016, 22, 961-973.
  • Biancone L., Onali S., Petruzziello C., Calabrese E., Pallone F.: Cancer and immunomodulators in inflammatory bowel diseases. Inflamm. Bowel. Dis. 2015, 21, 674-698.
  • Cerquetella M., Spaterna A., Laus F., Tesei B., Rossi G., Antonelli E., Villanacci V., Bassotti G.: Inflammatory bowel disease in the dog: Differences and similarities with humans. World J. Gastroenterol. 2010, 19, 1050-1056.
  • Derikx L. A., Nissen L. H., Drenth J. P., van Herpen C. M., Kievit W., Verhoeven R. H., Mulders P. F., Hulsbergen-van de Kaa C. A., Boers-Sonderen M. J., van den Heuvel T. R., Pierik M., Nagtegaal I. D., Hoentjen F.: Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 2015, 6, 38336-38347.
  • Gryzinska M., Andraszek K., Jocek G.: DNA methylation analysis of the gene CDKN2B in Gallus gallus (Chicken). Folia Biologica (Kraków) 2013, 61, 165-171.
  • Hartnett L., Egan L. J.: Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 2012, 33, 723-731.
  • Jones R., Scobey M., Cheng J.: The Risk of Colon Cancer in Inflammatory Bowel Disease. J. Gastroint. Dig. Syst. 2014, 4, 723-731.
  • Kanaan Z., Rai S. N., Eichenberger M. R., Barnes C., Dworkin A. M., Weller C., Cohen E., Roberts H., Keskey B., Petras R. E., Crawford N. P., Galandiuk S.: Differential micro RNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum. Mutat. 2012, 33, 551-560.
  • Karczewski J., Mazur M., Rychlewska-Hańczewska A., Adamski Z.: Rola limfocytów Th17 w patogenezie raka jelita grubego. Postepy Hig. Med. Dosw. 2014, 68, 42-47.
  • Korolkova O. Y., Myers J. N., Pellom S. T., Wang L., M’Koma A. E.: Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn’s Colitides. Clin. Med. Insights Gastroenterol. 2015, 8, 29-44.
  • Kraak L. van Der, Gros P., Beauchemin N.: Colitis-associated colon cancer: Is it in your genes? World J. Gastroenterol. 2015, 21, 11688-11699.
  • Lau T. P., Roslani A. C., Lian L. H., Lee P. C., Hilmi I., Goh K. L., Chua K. H.: NOD2/CARD15 variants in Malaysian patients with sporadic colorectal cancer. Genet. Mol. Res. 2014, 13, 7079-7085.
  • Low D., Subramaniam R., Lin L., Aomatsu T., Mizoguchi A., Ng A., DeGruttola A. K., Lee C. G., Elias J. A., Andoh A., Mino-Kenudson M., Mizoguchi E.: Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9. Oncotarget. 2015, 6, 36535-36550.
  • Meyer L., Simian D., Kronberg U., Estay C., Lubascher J., Figueroa C., Quera R.: Development of malignant tumors in patients with inflammatory bowel disease. Rev. Med. Chil. 2015, 143, 834-840.
  • Robles A. I., Traverso G., Zhang M., Roberts N. J., Khan M. A., Joseph C., Lauwers G. Y., Selaru F. M., Popoli M., Pittman M. E., Ke X., Hruban R. H., Meltzer S. J., Kinzler K. W., Vogelstein B., Harris C. C., Papadopoulos N.: Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. Gastroenterology 2016, 150, 931-943.
  • Rossi R. E., Conte D., Massironi S.: Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur. J. Gastroenterol. Hepatol. 2016, 28, 123-131.
  • Rubin D. C., Shaker A., Levin M. S.: Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front. Immunol. 2012, 3, 107.
  • Thagia I., Shaw E. J., Smith E., Else K. J., Rigby R. J.: Intestinal epithelial suppressor of cytokine signaling 3 enhances microbial-induced inflammatory tumor necrosis factor-α, contributing to epithelial barrier dysfunction. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 308, 25-31.
  • Volodko N., Salla M., Eksteen B., Fedorak R. N., Huynh H. Q., Baksh S.: TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. World J. Gastroenterol. 2015, 21, 10358-10366.
  • Walczak A., Przybylowska K., Dziki L., Sygut A., Chojnacki C., Chojnacki J., Dziki A., Majsterek I.: The lL-8 and IL-13 Gene Polymorphisms in Inflammatory Bowel Disease and Colorectal Cancer. DNA Cell. Biol. 2012, 31, 1431-1438.
  • Wang Z. H., Fang J. Y.: Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Surveillance. Gastrointest. Tumors. 2014, 1, 146-154.
  • Willard M. D.: Feline inflammatory bowel disease: a review. J. Feline Med. Surg. 1999, 1, 155-164.
  • Yi J. M., Kim T. O.: Epigenetic alterations in inflammatory bowel disease and cancer. Intest. Res. 2015, 13, 112-121.
  • Yoshimi K., Tanaka T., Serikawa T., Kuramoto T.: Tumor suppressor APC protein is essential in mucosal repair from colonic inflammation through angiogenesis. Am. J. Pathol. 2013, 182, 1263-1274.
  • Zhiqin W., Palaniappan S., Raja Ali R. A.: Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. Intest. Res. 2014, 12, 194-204.

Typ dokumentu



Identyfikator YADDA

JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.